• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Lai Gang

    3/18/26 8:26:07 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UPC alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    Lai Gang

    (Last)(First)(Middle)
    265 JINGJIU AVENUE
    JINGGANGSHAN ECON. AND TECH. DEV. ZONE

    (Street)
    JI'AN, JIANGXI343100

    (City)(State)(Zip)

    CHINA

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/18/2026
    3. Issuer Name and Ticker or Trading Symbol
    Universe Pharmaceuticals INC [ UPC ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    XOfficer (give title below)Other (specify below)
    Chief Executive Officer
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Class B ordinary shares, par value US$0.00001 per share3,467IBy Sununion Holding Group Limited(1)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    1. Represents 3,467 Class B ordinary shares held by Sununion Holding Group Limited, a business company incorporated in the British Virgin Islands, which is owned as to 100% and controlled by Gang Lai. The registered address of Sununion Holding Group Limited is Vistra Corporate Services Centre, Wickhams Cay II, Road Town, Tortola, VG1110, British Virgin Islands.
    /s/ Gang Lai03/18/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $UPC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UPC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $UPC
    SEC Filings

    View All

    SEC Form 6-K filed by Universe Pharmaceuticals Inc.

    6-K - Universe Pharmaceuticals INC (0001809616) (Filer)

    2/11/26 4:06:12 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 20-F filed by Universe Pharmaceuticals Inc.

    20-F - Universe Pharmaceuticals INC (0001809616) (Filer)

    1/28/26 7:34:16 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Universe Pharmaceuticals Inc.

    SCHEDULE 13G/A - Universe Pharmaceuticals INC (0001809616) (Subject)

    1/7/26 3:37:31 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by Universe Pharmaceuticals Inc.

    3 - Universe Pharmaceuticals INC (0001809616) (Issuer)

    3/18/26 8:27:11 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Universe Pharmaceuticals Inc.

    3 - Universe Pharmaceuticals INC (0001809616) (Issuer)

    3/18/26 8:25:06 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Universe Pharmaceuticals Inc.

    3 - Universe Pharmaceuticals INC (0001809616) (Issuer)

    3/18/26 8:20:47 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Universe Pharmaceuticals INC Announces Effective Date of Dual-Class Share Structure

    Ji'an, Jiangxi, China, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ:UPC) ("Universe Pharmaceuticals" or the "Company"), a pharmaceutical producer and distributor in China, today announced that all conditions to the implementation of its dual-class share structure have been satisfied and that its dual-class share structure will become effective on the Nasdaq Capital Market on February 13, 2026. In connection with the implementation of its dual-class share structure, the Company amended and restated its memorandum and articles of association and the Company's authorized share capital was changed to US$20,000 divided into 1,800,000,000 class A ordinary shares of pa

    2/11/26 4:05:00 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Universe Pharmaceuticals INC Announces Share Consolidation

    Jiangxi, China, March 20, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ:UPC) ("Universe Pharmaceuticals" or the "Company"), a pharmaceutical producer and distributor in China, today announced that the Company plans to effect a share consolidation of 40 ordinary shares with par value of US$0.28125 per share each in the Company's issued and unissued share capital into one (1) ordinary share with par value of US$11.25 (the "Share Consolidation"). As a result of the Share Consolidation, each 40 pre-consolidation ordinary shares outstanding will automatically combine and convert to one issued and outstanding ordinary share without any action on the part of the shareholders. Th

    3/20/25 8:30:00 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Universe Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual Report

    Ji'an, Jiangxi, China, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the "Company") (NASDAQ:UPC), a pharmaceutical producer and distributor in China, today announced that on February 19, 2025, the Company received a staff determination notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that it is delinquent in filing its Annual Report on Form 20-F for the fiscal year ended September 30, 2024 (the "Form 20-F") and that this matter serves as an additional basis for delisting the Company's securities from Nasdaq. The failure to timely file the Form 20-F is a violation of Nasdaq Listing Rule 5250(c)(1). The Com

    2/25/25 4:10:00 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Universe Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Universe Pharmaceuticals INC (0001809616) (Subject)

    2/14/23 2:14:41 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Universe Pharmaceuticals Inc.

    SC 13G - Universe Pharmaceuticals INC (0001809616) (Subject)

    2/11/22 8:00:43 AM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Universe Pharmaceuticals Inc.

    SC 13G - Universe Pharmaceuticals INC (0001809616) (Subject)

    12/28/21 4:10:53 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $UPC
    Leadership Updates

    Live Leadership Updates

    View All

    Universe Pharmaceuticals INC Appoints Mr. Baochang Liu as Chief Operating Officer

    Ji'an, Jiangxi, China, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the "Company") (NASDAQ:UPC), a pharmaceutical producer and distributor in China, today announced that the Company appointed Mr. Baochang Liu as its Chief Operating Officer, effective December 1, 2021. Mr. Baochang Liu has over 17 years of experience in pharmaceutical marketing. Mr. Baochang Liu has been working as the vice president of marketing and general manager of OTC department at China Shineway Pharmaceutical Group Ltd. since December 2019. Mr. Baochang Liu served as the general manager of OTC department at Chengdu Kanghong Pharmaceutical Group Co., Ltd. from November 2015 to December 2019. Prior

    12/15/21 4:30:00 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care